• Daxor received U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor,” expanding its blood volume measurement technology into remote monitoring.
• The system uses an initial absolute baseline blood volume measurement, then updates total blood volume using ongoing hematocrit readings from wearable optical sensors.
• Daxor expects the approach to support continuous tracking for chronic fluid-management conditions, including heart failure, without repeated tracer injections.
• The patent also covers automated alerts when blood volume measures move beyond patient-specific thresholds, aiming to guide clinical intervention.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daxor Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020800PRIMZONEFULLFEED9729850) on June 02, 2026, and is solely responsible for the information contained therein.